Medscape www.medscape.com

References for:
Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Site- and Spectrum-of-Care Strategies for Optimizing Patient Outcomes in NSTE-ACS

[J Invasive Cardiol 15(9):536-553, 2003. © 2003 Health Management Publications, Inc.]

  1. Antman EM, Cohen M, Bernink PJ, et al. The TIMI Risk Score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
  2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI)-11B trial. Circulation 1999;100:1593-1601.
  3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
  4. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
  5. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction (published erratum appears in N Engl J Med 1998;339:415); N Engl J Med 1998;338:1488-1497.
  6. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous fibrinolytic treatment in acute myocardial infarction. Lancet 1986;8478:397.
  7. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST elevation myocardial infarction: The British Heart Foundation RITA 3 Randomised Trial. Lancet 2002;360:743-751.
  8. The Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multicentre study. Lancet 1999;354:708.
  9. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndrome receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-244.
  10. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction:an open multicenter randomized trial. The VINO Study. Eur Heart J 2002;23:230-238.
  11. Neuman, Heartwire, November 20, 2002.
  12. Michalis LK, Papamichail N, Katsouras C, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (The EVET Study). J Am Coll Cardiol 2001;37:365A.
  13. Ferguson JJ. NICE-3: A prospective, open label, non-randomized observational safety study on the combination of LMW heparin with the clinically available GP IIb/IIIa antagonists in 600 patients with acute coronary syndromes. Eur Heart J 2000;21:599.
  14. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention in unstable angina patients pretreated with subcutaneous enoxaparin. Eur Heart J 2000;21:599.
  15. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
  16. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa Blockade. Circulation 1999;99:1951.
  17. Dudek D, Zymek P, Bartus S, et al. Prospective randomized comparison of enoxaparin versus unfractionated heparin for elective percutaneous coronary interventions among ticlopidine-pretreated patients. Eur Heart J 2000;21:381.
  18. Young JJ, Keriakes DJ, Grines CL, et al. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. J Invas Cardiol 2003;12(Suppl E):E14-E18.
  19. Martin JL, Fry ETA, Serano A, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI Study. Eur Heart J 2001;22(Suppl):14.
  20. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
  21. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41:20-25.
  22. ENOX® package insert. ENOX® is a trademark of Pharmanetics, Inc. Rapidpoint is a trademark of Bayer Corporation. Lovenox and Clexane are registered trademarks of Aventis Pharmaceuticals Products, Inc. ©2002 Pharmanetics, Inc. 9401 Globe Center Drive, Morrisville, NC 27560. US Patents #4,849,340; #5,110,727; #5,350,676.
  23. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
  24. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
  25. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
  26. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invas Cardiol 2000;12(Suppl A):1A-5A.
  27. Ferguson JJ. NICE-3 Trial Results. Aug. 27, 2001; Presented at the 22nd Congress of the European Society of Cardiology.
  28. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002;144:615-624.
  29. Cohen M, Theroux P, Frey MJ, et al. Antithrombotic combination using tirofiban and enoxaparin: The ACUTE II Study (Abstr). Circulation 2000;102(Suppl).
  30. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invas Cardiol 2000;12(Suppl E):E14-E18.
  31. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
  32. Schriger DL, Herbert ME. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: Does the enthusiasm exceed the science? Ann Emerg Med 2001;38:229-240.
  33. Fox KA, Antman EM, Cohen M, et al. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-482.
  34. Collet JP, Montalescot G, Golmard JL, et al. Safety and efficacy of subcutaneous enoxaparin in early invasive strategy of unstable angina. American College of Cardiology Poster Presentation, April 1, 2003; presentation 1176-199.
  35. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-244.
  36. Mukherjee D, Mahaffey KW, Moliterno DJ, et al. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network B (PARAGON B). Am Heart J 2002;144:995-1002.
  37. The ASSENTInvestigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT randomised trial in acute myocardial infarction. Lancet 2001;358:605.
  38. Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q wave myocardial infarction. Semin Thromb Hemost 1999;25(Suppl 3):113.
  39. Wallentin L. Efficacy of low-molecular-weight heparin in acute coronary syndromes. Am Heart J 2000;139(2 Part 2):S29.
  40. Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. Pharmacoeconomics 1999;16(5 pt 2):533.
  41. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events (Unstable Angina or Non-Q Wave Myocardial Infarction). Circulation 1998;97:1702.
  42. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998;5:92.
  43. Detournay B, Huet X, Fagnani F, et al. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French substudy of the ESSENCE trial. Pharmacoeconomics 2000;18:83.
  44. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS Randomized Trial. Lancet 2001;357:1915-1924.
  45. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
  46. Morrow DA, Antman EM, Snapinn S, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223-229.
  47. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
  48. Lincoff M, Harrington R, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2000;102:1093-1100.
  49. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
  50. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study. Lancet 2001;358:527.
  51. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20:2316.
  52. Steinhubl SR, Berger PB, Mann JT III, et al., for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;2411-2420. Available at: http://jama. ama-assn.org.
  53. CREDO: Clopidogrel before elective PCI cuts 1-month event risk. Heartwire: News; Sept. 25, 2002.
  54. Clopidogrel loading dose improves platelet inhibition regardless of time of loading. Heartwire: News, Sept. 7, 2001.
  55. Lincoff AM, Bittl JA, Harrington RA, et al., for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
  56. Bosch X, Marrugat JP. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. In: The Cochrane Library, Issue 2, 2002.